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Despite its rigid structure, bone is a dynamic tissue that is in constant remodeling. This 
process requires the action of the bone-resorbing osteoclasts and the bone-synthesing 
osteoblasts. One of the adverse effects attributed to some antihypertensive agents is the 
ability to alter normal bone metabolism. However, their effective actions on human 
bone cells remain to be clarified. In this work, the effects of five calcium channel 
blockers, a class of antihypertensive drugs (AHDs), were investigated on osteoclastic 
differentiation. 
Osteoclastic cell cultures were established from precursor cells isolated from human 
peripheral blood, and were maintained in the absence (control) or in the presence of 10
-
8
-10
-4
 M of different AHDs (amlodipine, felodipine, diltiazem, lercanidipine and 
nifedipine). Cell cultures were characterized throughout a 21 day period for tartrate-
resistant acid phosphatase (TRAP) activity, number of TRAP+ multinucleated cells, 
presence of cells with actin rings and expressing vitronectin and calcitonin receptors, 
and apoptosis rate. Also, the involvement of several signaling pathways on the cellular 
response was addressed. 
It was observed that the tested AHDs had the ability to differentially affect 
osteoclastogenesis. At low doses, amlodipine and felodipine caused an increase on 
osteoclastic differentiation, while the other drugs inhibited it. At higher doses, all the 
molecules caused a decrease on the process. The tested AHDs also showed different 
effects on the analysed signaling pathways. 
In conclusion, AHDs appeared to have a direct effect on human osteoclast precursor 
cells, affecting their differentiation. Interestingly, some of them increased while others 
inhibited the process. Unraveling the mechanisms beneath these observations might 
help to explain the adverse effects on bone tissue described for this drug class.  
